Literature DB >> 8907818

Sarcoidosis presenting with prolonged fever in a patient with sickle cell anemia.

E D Chan1, L S Terada, M I Schwarz.   

Abstract

Although the leading causes of fever and pulmonary infiltrates in sickle cell patients are acute bacterial pneumonia and the acute chest syndrome, the former is usually responsive to antibiotics and not protracted, and the clinical course of the latter is short and self-limited. A patient with sickle cell anemia presented with fever and pulmonary infiltrates of several weeks duration that were unresponsive to antibiotics. Gross endobronchial abnormalities were noted on bronchoscopy, and the biopsies were consistent with sarcoidosis. The diagnosis of sarcoidosis can be difficult to establish in a patient with sickle cell anemia and protracted fever since both disorders are associated with chronic interstitial changes on the chest radiograph as well as restrictive physiology.

Entities:  

Mesh:

Year:  1995        PMID: 8907818      PMCID: PMC2607955     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  2 in total

1.  HEMOGLOBIN STUDIES IN SARCOIDOSIS.

Authors:  R J HIRSCHMAN; C J JOHNS
Journal:  Ann Intern Med       Date:  1965-01       Impact factor: 25.391

2.  FREQUENCY OF HEMOGLOBINOPATHIES IN SARCOIDOSIS.

Authors:  S R GREENBERG; J ATWATER; H L ISRAEL
Journal:  Ann Intern Med       Date:  1965-01       Impact factor: 25.391

  2 in total
  2 in total

Review 1.  Sickle cell anemia patient with sarcoidosis-associated inguinal lymph node and lung infiltration.

Authors:  Birol Güvenç; Cagatay Unsal; Ismail Hanta; Aydan Unsal; Hakan Güvenç
Journal:  J Natl Med Assoc       Date:  2005-06       Impact factor: 1.798

Review 2.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.